MetLife (MET)
NYSEFinancialsInsurance - LifeSnapshot 2026-10-29
$100.02-0.80%
Close 2026-10-30 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-10-29
Research Workspace
Put MET beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMostly healthy — no soft spokes
MetLife’s steady growth, backed by cash earnings, supports its durable franchise and expansion through acquisitions. Revenue growth accelerated from 5% in Q1 FY2026 to 7% in Q2 FY2026. Q2 FY2026 non-GAAP earnings beat consensus by 5.7%. MetLife trades at 2× book value versus a 1× peer median, near its 2× history. The price reflects less growth than our forecast, despite that peer premium. The premium could compress if the franchise does not justify the gap; our model puts next-quarter miss probability near 22%. Peer multiples imply a price about 51% above where it trades. This read is provisional.
Trailing returns as of 2026-10-30. MET is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering MET (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for MET in the last 4 months.
Continue this research
Compare MET with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MET Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put MET next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Potential acquisition aligns with growth and revenue objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $100.02
The last 12 months of price, then the range of analyst 12-month targets from today’s $100.02.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Acquisition supports growth and capital allocation objectives.
Advances: Deliver double-digit adjusted earnings per share growth
Growth plan aligns with EPS growth objective.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Buyback supports capital allocation and shareholder returns.
Economic concerns may impact premium growth and overall revenues.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Share repurchase supports disciplined capital allocation and shareholder returns.
Advances: Deliver double-digit adjusted earnings per share growth
20% EPS growth supports double-digit growth objective.
Advances: Deliver double-digit adjusted earnings per share growth
Earnings call confirms strong EPS growth and ROE.
